Cannara Biotech Inc. provided preliminary unaudited revenue guidance for the three-month period ended May 31, 2021. The Company expects total revenue, net of excise tax, for the third quarter ended May 2021 to be approximately $7.1 million, representing a $5.1 million increase compared to the second quarter of 2021.